At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed breast cancer with HER-2 overexpression
- ✓Metastatic or chest wall recurrent disease
- ✓Recurrent or progressive disease on prior trastuzumab, or relapsed within 3 months of adjuvant trastuzumab
- ✓Measurable disease ≥20 mm by conventional imaging or ≥10 mm by spiral CT
- ✕No untreated brain metastases; treated metastases allowed if not the sole measurable disease site
- ✕No active or ongoing infection
- ✕No symptomatic congestive heart failure, unstable angina, or cardiac arrhythmia
- ✕No concurrent combination antiretroviral therapy for HIV-positive patients
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Trastuzumab (Herceptin) in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer
In Brief
A Phase 2 clinical trial evaluating vorinostat and trastuzumab for Breast Cancer and 5 related conditions. Completed, enrolled 16 participants across 25 sites.
Detailed Summary
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with trastuzumab and to see how well they work in treating patients with metastatic breast canceror breast cancer that has recurred in the chest wall. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Vorinostat and trastuzumab also may stop the growth of tumor cells by blocking blood flow to the tumor. Giving vorinostat together with trastuzumab may be a better way to block tumor growth.
Study Details
Timeline
Interventions
Given orally
Given IV